Ultimo aggiornamento :
08/05/2024
Anticoagulante   Tirofiban  
Iniezione
Stabilità in soluzione Stabilità in miscela Fattori che influenzano la stabilità Compatibilità Metodo di iniezione Bibliografia Pdf

Nome commerciale   Nome commerciale     

Trade names are indicative and excipients composition can be different depending on the country and manufacturers

Aggrastat Arabia Saudita, Australia, Austria, Belgio, Canada, Danimarca, Emirati Arabi Uniti, Finlandia, Germania, Gran Bretagna, Iran, Irlanda, Italia, Lussemburgo, Malaysia, Norvegia, Nuova Zelanda, Paesi Bassi, Polonia, Portogallo, Stati Uniti d’America, Svezia, Svizzera, Turchia, Ungheria
Agrastat Argentina, Brasile, Chile, Colombia, Ecuador, Egitto, Francia, Marocco, Messico, Perù, Spagna, Venezuela
Thrombostat Turchia
Tirofiban Germania, Spagna
Tiroprest Turchia
Welban Spagna
Xtraban India
Bibliografia   Iniezione   Bibliografia : Tirofiban  
Tipo Pubblicazione
1071 Rivista Bergquist PA, Zimmermann J, Kenney RR, Han RYH, Hunke WA.
Stability of tirofiban hydrochloride in three commonly used IV solutions and polyvinyl chloride administration sets.
Am J Health-Syst Pharm 1999 ; 56: 1627-1629.
1420 Rivista Bergquist PA, Hunke WA, Reed RA, Manas D, Forsyth RJ, Kenney RR, Cook J, Holahan M.
Compatibility of tirofiban HCl with dopamine HCl, famotidine, sodium heparin, lidocaine HCl and potassium chloride during simulated Y-site administration.
J Clin Pharm Ther 1999 ; 24: 125-132.
1508 Rivista Voirol P, Berger-Gryllaki M, Pannatier A, Eggimann P, Sadeghipour F.
Visual compatibility of insulin aspart with intravenous drugs frequently used in ICU.
EJHP 2015 ;22:123-124.
1512 Laboratorio Tirofiban (Aggrastat®) - Summary of Product Characteristics
Beacon Pharmaceuticals Ltd 2015
1600 Rivista Garabito MJ, Jimenez L, Bautista J, Santos-Rubio MD, Perez Rodrigo I.
Stability of tirofiban hydrochloride in 0.9% sodium chloride injection for 30 days.
Am J Health-Syst Pharm 2001 ; 58: 1850-1851.
1603 Rivista Bergquist PA, Manas D, Hunke WA, Reed RA.
Stability and compatibility of tirofiban hydrochloride during simulated Y-site administration with other drugs.
Am J Health-Syst Pharm 2001 ; 58: 1218-1223.
1611 Rivista Chalmers JR, Bobek MB, Militello MA.
Visual compatibility of amiodarone hydrochloride injection with various intravenous drugs.
Am J Health-Syst Pharm 2001 ; 58: 504-506.
1713 Rivista Trissel LA, Saenz CA.
Compatibility screening of bivalirudin during simulated Y-site administration with other drugs.
Int J Pharm Compound 2002 ; 6: 311-315.
2004 Rivista Patel K, Hursting MJ.
Compatibility of argatroban with abciximab, eptifibatide, or tirofiban during simulated Y-site administration.
Am J Health-Syst Pharm 2005 ; 62: 1381-1384.
3823 Rivista Juan E.P, Palau M.M, Cerd? S.A, Rubert M.A, Nicolau B.R.
Compatibilité physique de médicaments administrés dans l’unité de soins intensifs
Pharmactuel 2015 ; 48, 3 : 146-152.

  Mentions Légales